US approval withdrawn
Assets whose US approval the FDA withdrew, with no current US approval in the markets shown.
Almotriptan (Axert)
Small moleculeUS approval withdrawn
Inotersen · Tegsedi
RNA / oligonucleotideUS approval withdrawn
Miglitol · Glyset
Small moleculeUS approval withdrawnNo recent activity
Panobinostat
Small moleculeUS approval withdrawn
Pramipexole · Sifrol/Mirapex
Small moleculeUS approval withdrawn
mesalamine (Asacol HD)
Small moleculeUS approval withdrawnNo recent activity
repaglinide · Prandin / NovoNorm
Small moleculeUS approval withdrawn